ea0082wd7 | Workshop D: Disorders of the adrenal gland | SFEEU2022
Virgo Elena
, Joseph Stonny
Lung cancer is the second most common cancer in the world with the leading position as a cause of oncological fatality. The immunotherapy is applied as the second line of chemotherapy, and seems a breakthrough therapy, promising a better quality of life to patients in the late stages of cancer. Pembrolizumab (also, known as MK-3475 or Keyruda) is a humanised antibody PD-1 receptor or antibody to programmed death ligand one. Side effects considered as acceptable and mostly pres...